Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial tests the safety, side effects studies chemotherapy followed by
chemotherapy at the same time as radiation therapy (chemoradiation) before surgery
(neoadjuvant) in treating patients with stage gastric (stomach) or gastroesophageal junction
cancer . Chemotherapy drugs, such as docetaxel, oxaliplatin , leucovorin, fluorouracil, and
capecitabine, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy
uses high energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy and
chemoradiation before surgery may make the tumor smaller and may reduce the amount of normal
tissue that needs to be removed.